39
Participants
Start Date
July 25, 2019
Primary Completion Date
March 31, 2022
Study Completion Date
July 7, 2022
IONIS GHR-LRx
Participants will receive IONIS GHR-LRx by subcutaneous injection.
Somatostatin Receptor Ligand (SRL)
Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
Magyar Honvedseg Allami Egeszsegugyi Kozpont, II. sz Belgyogyaszat Osztaly, Budapest
Vaidoto Urbanaviciaus Individuali imone - Endokrinologijos klinika, Vilnius
Memorial Sloan Kettering Cancer Center, New York
Clinical Center of Serbia, Belgrade
University of Alabama at Birmingham, Birmingham
Cleveland Clinic, Cleveland
Northwestern University, Evanston
Palm Research Center, Inc., Las Vegas
Oregon Health & Science University, Portland
"Federal State Budget Institution National Medical Research Center of Endocrinology of the Ministry of Healthcare of the Russian Federation", Moscow
I.M. Sechenov Moscow First State Medical University, Moscow
State Budget Healthcare Institution of the Tver Region (Regional Clinical Hospital), Tver'
Almazov National Medical Research Centre, Saint Petersburg
Interregional Clinical Diagnostic Center, Kazan'
Orenburg Regional Clinical Hospital, Orenburg
Novosibirsk State Regional Clinical Hospital, Novosibirsk
Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev, Kemerovo
Multi-field Medical Clinic Anturium LLC, Barnaul
Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos - Endocrinology clinic, Kaunas
"Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o. o.", Krakow
Twoja Przychodnia - Centrum Medyczne Nowa Sol, Nowa Sól
Mazowiecki Szpital Brodnowski, Warsaw
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY